Trial · NCT03554291
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Six-minute Walk Distance | Famotidine | -17.0 | 95% Confidence Interval -43.6 to 9.7 | meters | |
| Change in Six-minute Walk Distance | Placebo | 4.7 | 95% Confidence Interval -20.1 to 29.6 | meters | |
| Chang in Log-transformed BNP | Famotidine | -0.05 | 95% Confidence Interval -0.16 to 0.26 | Log of pg/mL | |
| Chang in Log-transformed BNP | Placebo | 0.08 | 95% Confidence Interval -0.12 to 0.27 | Log of pg/mL | |
| Proportion of Participants With New York Heart Association (NYHA) Functional Class of I or II at Week 24 | Famotidine | 0.71 | 95% Confidence Interval 0.54 to 0.85 | Proportion participants NYHA class I/II | |
| Proportion of Participants With New York Heart Association (NYHA) Functional Class of I or II at Week 24 | Placebo | 0.53 | 95% Confidence Interval 0.36 to 0.69 | Proportion participants NYHA class I/II | |
| Change in Right Ventricular Morphology by Echocardiogram (RV Dilation and TAPSE) | Famotidine | RV dilation | -1.5 | 95% Confidence Interval -3.2 to 0.3 | RV basal diameter (cm)/TAPSE (mm) |
| Change in Right Ventricular Morphology by Echocardiogram (RV Dilation and TAPSE) | Placebo | RV dilation | 0.9 | 95% Confidence Interval -0.9 to 2.6 | RV basal diameter (cm)/TAPSE (mm) |
| Change in Right Ventricular Morphology by Echocardiogram (RV Dilation and TAPSE) | Famotidine | TAPSE | 0.1 | 95% Confidence Interval -1.2 to 1.3 | RV basal diameter (cm)/TAPSE (mm) |
| Change in Right Ventricular Morphology by Echocardiogram (RV Dilation and TAPSE) | Placebo | TAPSE | 0.7 | 95% Confidence Interval -0.6 to 1.9 | RV basal diameter (cm)/TAPSE (mm) |
| Change in Health Related Quality of Life (emPHasis-10 Questionnaire) | Famotidine | -1.7 | 95% Confidence Interval -4.2 to 0.8 | score on a scale | |
| Change in Health Related Quality of Life (emPHasis-10 Questionnaire) | Placebo | -1.3 | 95% Confidence Interval -3.9 to 1.2 | score on a scale | |
| Percent of Participants by Arm Who Added PAH Focused Care (Increased Diuretics, Escalating Doses of Pulmonary Vasodilators, and/or Adding Additional Pulmonary Vasodilators) Over 24 Weeks. | Famotidine | 8.1 | 95% Confidence Interval -0.3 to 18.9 | model-based percentage of participants | |
| Percent of Participants by Arm Who Added PAH Focused Care (Increased Diuretics, Escalating Doses of Pulmonary Vasodilators, and/or Adding Additional Pulmonary Vasodilators) Over 24 Weeks. | Placebo | 5.3 | 95% Confidence Interval -1.8 to 12.5 | model-based percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03554291/results